secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001999371-24-005990
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix reports Q1 net loss $14.9M; cash at $7.0M; advancing Tonmya NDA
---------------------------------------------------------------------

- Net product revenue $2.5M from Zembrace/Tosymra; net loss $(14.9)M ($0.18/share) vs $(33.0)M ($3.21) YoY.
- Cash $7.0M at Mar 31, 2024, down from $24.9M Dec 31; net cash used in ops $17.6M.
- On track to submit NDA for Tonmya in H2 2024; pre-NDA FDA meeting scheduled Q2 2024.
- Raised $4.4M in registered direct offering on Apr 1, 2024 (post-quarter).
- R&D expenses down to $12.9M from $26.5M; G&A up to $9.3M from $7.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937124005990/0001999371-24-005990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937124005990/tnpx_8k-051324.htm
  HTML page:      https://secwatch.observer/filing/0001999371-24-005990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer